← Back to Search

Thiazolidinedione

Rosiglitazone for Thyroid Cancer

Phase 2

Waitlist Available

Led By Electron Kebebew, MD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of differentiated thyroid cancer

More than 3 months since prior chemotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying the effects of rosiglitazone on patients with locoregionally extensive or metastatic thyroid cancer.

Who is the study for?

This trial is for adults with advanced thyroid cancer who've had a scan in the last 18 months, have certain levels of thyroglobulin, and show little to no uptake on radioactive iodine scans. They should not be pregnant or nursing, must use contraception if fertile, and can't have severe heart disease or allergies to thiazolidinediones.Check my eligibility

What is being tested?

The study tests how well rosiglitazone works in making thyroid tumor cells more sensitive to radioactive iodine. It's for those whose cancer has spread locally or further and who didn't respond well to surgery and radioactive iodine treatment.See study design

What are the potential side effects?

Rosiglitazone may cause fluid retention leading to swelling, weight gain, fatigue, headache, muscle pain; it might also affect liver function and increase risk of bone fractures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with differentiated thyroid cancer.

Select...

It has been over 3 months since my last chemotherapy session.

Select...

My cancer has spread to nearby areas or other parts of my body.

Select...

I have had thyroid surgery and radioactive iodine treatment, but my condition did not improve.

Select...

My heart condition does not severely limit my daily activities.

Select...

I have no cancer other than possibly basal cell skin cancer.

Select...

I have never received more than 800 mCi of radioiodine treatment.

Select...

My condition cannot be treated with surgery.

Select...

I am 18 years old or older.

Select...

I am not taking levothyroxine.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Radioiodine uptake and thyroglobulin level at 6 months and 1 year

Secondary outcome measures

Side effects of drug at 2 months

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,667 Previous Clinical Trials

40,926,141 Total Patients Enrolled

University of California, San FranciscoLead Sponsor

2,506 Previous Clinical Trials

15,238,530 Total Patients Enrolled

Electron Kebebew, MDPrincipal InvestigatorUniversity of California, San Francisco

4 Previous Clinical Trials

505 Total Patients Enrolled

Media Library

Rosiglitazone (Thiazolidinedione) Clinical Trial Eligibility Overview. Trial Name: NCT00098852 — Phase 2

Head and Neck Cancers Research Study Groups:

Head and Neck Cancers Clinical Trial 2023: Rosiglitazone Highlights & Side Effects. Trial Name: NCT00098852 — Phase 2

Rosiglitazone (Thiazolidinedione) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00098852 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How secure are patients who utilize this particular remedy?

"There is limited data confirming the safety of this intervention, so it earned a score of 2."

Answered by AI

Are there any vacancies open in this clinical assessment for participants?

"The information on clinicaltrials.gov reveals that this trial is not currently seeking patients, as the last update was posted in January of 2014. Despite this inactive status, there are 476 other studies actively recruiting participants right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

2004. "Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00098852.

All > Thyroid Cancer > Thyroid